DXCM – DexCom, Inc.
DexCom, Inc.DXCM
$66.14Name : DexCom, Inc.
Sector : Healthcare
Industry: Medical Devices
Mark. Cap: $25,933,957,120.00
EPSttm : 1.42
DexCom, Inc.
$66.14
1.72%$1.16Float Short %
2.85
Margin Of Safety %
16
Put/Call OI Ratio
0.85
EPS Next Q Diff
0.03
EPS Last/This Y
0.56
EPS This/Next Y
0.45
Price
66.11
Target Price
101.61
Analyst Recom
1.48
Performance Q
-14.94
Relative Volume
0.99
Beta
1.4
Ticker: DXCM
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-12 | DXCM | 70.76 | 0.78 | 1.44 | 133947 |
| 2025-03-13 | DXCM | 68.5 | 0.79 | 6.65 | 136636 |
| 2025-03-14 | DXCM | 70.67 | 0.78 | 0.72 | 136398 |
| 2025-03-17 | DXCM | 71.35 | 0.77 | 0.63 | 135045 |
| 2025-03-18 | DXCM | 70.69 | 0.77 | 0.64 | 137250 |
| 2025-03-19 | DXCM | 73.41 | 0.75 | 0.22 | 137493 |
| 2025-03-20 | DXCM | 75.09 | 0.74 | 1.68 | 138940 |
| 2025-03-21 | DXCM | 73.86 | 0.73 | 1.08 | 140017 |
| 2025-03-24 | DXCM | 75.32 | 0.79 | 0.42 | 112885 |
| 2025-03-25 | DXCM | 73.56 | 0.78 | 1.52 | 114281 |
| 2025-03-26 | DXCM | 72.12 | 0.79 | 1.33 | 114879 |
| 2025-03-27 | DXCM | 69.43 | 0.80 | 2.09 | 115711 |
| 2025-03-28 | DXCM | 68.34 | 0.77 | 0.88 | 117646 |
| 2025-03-31 | DXCM | 68.28 | 0.83 | 1.11 | 113528 |
| 2025-04-01 | DXCM | 67.33 | 0.82 | 1.91 | 115906 |
| 2025-04-02 | DXCM | 68.09 | 0.83 | 0.91 | 120841 |
| 2025-04-03 | DXCM | 61.81 | 0.83 | 3.50 | 122434 |
| 2025-04-04 | DXCM | 60.09 | 0.83 | 3.25 | 125212 |
| 2025-04-07 | DXCM | 61.59 | 0.87 | 0.26 | 124293 |
| 2025-04-08 | DXCM | 60.76 | 0.86 | 5.73 | 125008 |
| 2025-04-09 | DXCM | 66.78 | 0.88 | 0.90 | 127440 |
| 2025-04-10 | DXCM | 67.37 | 0.86 | 1.39 | 128995 |
| 2025-04-11 | DXCM | 66.15 | 0.85 | 0.42 | 128849 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-12 | DXCM | 70.81 | 1.9 | 87.2 | 2.02 |
| 2025-03-13 | DXCM | 68.49 | 1.9 | 54.9 | 2.02 |
| 2025-03-14 | DXCM | 70.69 | 1.9 | 106.9 | 2.02 |
| 2025-03-17 | DXCM | 71.35 | 1.9 | 88.4 | 2.02 |
| 2025-03-18 | DXCM | 70.71 | 1.9 | 73.6 | 2.02 |
| 2025-03-19 | DXCM | 73.38 | 1.9 | 111.5 | 2.02 |
| 2025-03-20 | DXCM | 75.11 | 1.9 | 99.9 | 2.02 |
| 2025-03-21 | DXCM | 73.88 | 1.9 | 67.6 | 2.02 |
| 2025-03-24 | DXCM | 75.32 | 1.9 | 97.5 | 2.02 |
| 2025-03-25 | DXCM | 73.55 | 1.9 | 61.8 | 2.02 |
| 2025-03-26 | DXCM | 72.13 | 1.9 | 65.2 | 2.02 |
| 2025-03-27 | DXCM | 69.43 | 2.2 | 50.6 | 2.02 |
| 2025-03-28 | DXCM | 67.74 | 2.2 | 60.7 | 2.02 |
| 2025-03-31 | DXCM | 68.26 | 2.2 | 87.9 | 2.02 |
| 2025-04-01 | DXCM | 67.32 | 2.2 | 70.2 | 2.02 |
| 2025-04-02 | DXCM | 68.14 | 2.2 | 91.5 | 2.02 |
| 2025-04-03 | DXCM | 61.75 | 2.2 | 5.8 | 2.02 |
| 2025-04-04 | DXCM | 59.88 | 2.2 | 56.5 | 2.02 |
| 2025-04-07 | DXCM | 61.59 | 2.2 | 105.5 | 2.02 |
| 2025-04-08 | DXCM | 60.69 | 2.2 | 69.3 | 2.02 |
| 2025-04-09 | DXCM | 66.79 | 2.2 | 163.1 | 2.02 |
| 2025-04-10 | DXCM | 67.31 | 2.2 | 87.4 | 2.02 |
| 2025-04-11 | DXCM | 66.11 | 3.1 | 67.4 | 2.02 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-12 | DXCM | -1.13 | -1.13 | 2.56 |
| 2025-03-13 | DXCM | -1.13 | -1.13 | 2.56 |
| 2025-03-14 | DXCM | -2.64 | -1.13 | 2.56 |
| 2025-03-17 | DXCM | -2.64 | -1.09 | 2.56 |
| 2025-03-18 | DXCM | -2.47 | -1.09 | 2.56 |
| 2025-03-19 | DXCM | -2.48 | -1.09 | 2.56 |
| 2025-03-20 | DXCM | -2.51 | -1.09 | 2.56 |
| 2025-03-21 | DXCM | -2.51 | -1.09 | 2.56 |
| 2025-03-24 | DXCM | -2.51 | -1.10 | 2.56 |
| 2025-03-25 | DXCM | -2.51 | -1.10 | 2.56 |
| 2025-03-26 | DXCM | -2.51 | -1.10 | 2.98 |
| 2025-03-27 | DXCM | -2.51 | -1.10 | 2.98 |
| 2025-03-28 | DXCM | -2.51 | -1.10 | 2.98 |
| 2025-03-31 | DXCM | -2.51 | -1.09 | 2.98 |
| 2025-04-01 | DXCM | -2.51 | -1.09 | 2.98 |
| 2025-04-02 | DXCM | -2.51 | -1.09 | 2.98 |
| 2025-04-03 | DXCM | -2.51 | -1.09 | 2.98 |
| 2025-04-04 | DXCM | -2.51 | -1.09 | 2.98 |
| 2025-04-07 | DXCM | -2.51 | -1.05 | 2.98 |
| 2025-04-08 | DXCM | -2.51 | -1.05 | 2.98 |
| 2025-04-09 | DXCM | -2.51 | -1.05 | 2.98 |
| 2025-04-10 | DXCM | -2.51 | -1.05 | 2.85 |
| 2025-04-11 | DXCM | -2.51 | -1.05 | 2.85 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.45
Avg. EPS Est. Current Quarter
0.33
Avg. EPS Est. Next Quarter
0.48
Insider Transactions
-2.51
Institutional Transactions
-1.05
Beta
1.4
Average Sales Estimate Current Quarter
1017
Average Sales Estimate Next Quarter
1129
Fair Value
76.6
Quality Score
89
Growth Score
98
Sentiment Score
88
Actual DrawDown %
59.9
Max Drawdown 5-Year %
-63.3
Target Price
101.61
P/E
46.43
Forward P/E
26.68
PEG
2.03
P/S
6.43
P/B
12.29
P/Free Cash Flow
41.12
EPS
1.42
Average EPS Est. Cur. Y
2.02
EPS Next Y. (Est.)
2.47
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
14.29
Relative Volume
0.99
Return on Equity vs Sector %
7.8
Return on Equity vs Industry %
9.4
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
67.4
DexCom, Inc.Sector: Healthcare
Industry: Medical Devices
Employees: 10200
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
stock quote shares DXCM – DexCom, Inc. Stock Price stock today
news today DXCM – DexCom, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch DXCM – DexCom, Inc. yahoo finance google finance
stock history DXCM – DexCom, Inc. invest stock market
stock prices DXCM premarket after hours
ticker DXCM fair value insiders trading